Tyrosine kinase inhibitors in systemic sclerosis: The case for imatinib Flavia V. CastelinoSwati BhattacharyyaJohn Varga Clinical Trials Report 21 July 2009 Pages: 161 - 163
Juvenile dermatomyositis: The role of cytokine gene polymorphisms in conferring risk and protection Emma Jane MacDermottThomas J. A. Lehman Clinical Trials Report 21 July 2009 Pages: 164 - 166
Bone health in systemic lupus erythematosus Pantelis PanopalisJinoos Yazdany OriginalPaper 21 July 2009 Pages: 177 - 184
Advances in renal bone disease: Osteoporosis and chronic kidney disease Sara BarnatoStuart M. Sprague OriginalPaper 21 July 2009 Pages: 185 - 190
New insights: Elevated follicle-stimulating hormone and bone loss during the menopausal transition Mone ZaidiHarry C. BlairLi Sun OriginalPaper 21 July 2009 Pages: 191 - 195
The use of doppler ultrasound to evaluate lesions of localized scleroderma Suzanne C. LiMelissa S. Liebling OriginalPaper 21 July 2009 Pages: 205 - 211
The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents Marisa Klein-GitelmanHermine I. Brunner OriginalPaper 21 July 2009 Pages: 212 - 217
Biomarkers for renal disease in childhood Lena DasHermine I. Brunner OriginalPaper 21 July 2009 Pages: 218 - 225
Ocular complications of childhood rheumatic diseases: Nonuveitic inflammatory eye diseases Andreas Reiff OriginalPaper 21 July 2009 Pages: 226 - 232